Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

Echo IQ Limited Faces FDA Setback on EchoSolv HF as It Weighs a New 510(k) Submission

Echo IQ Limited Faces FDA Setback on EchoSolv HF as It Weighs a New 510(k) Submission Source: Kapitales Research

Highlights:

  • Echo IQ Limited said the US FDA upheld its "not substantially equivalent" determination for EchoSolv HF after reviewing the company's appeal.

  • The company is weighing its options, including engaging with the FDA, a new 510(k) submission and further review under FDA procedures.

  • EchoSolv AS is unaffected and remains FDA-cleared and commercially available in the US.

Introduction

Medical technology investors received a regulatory update on 19 November 2026. The Sydney-based AI and medical technology company told the market that the US regulator had completed its supervisory review of an appeal. Echo IQ Limited (ASX: EIQ) is currently trading at AU$0.325.

FDA Upholds Its Determination

On 19 November 2026, Echo IQ advised that the US Food and Drug Administration had completed its supervisory review of the company's appeal against a "not substantially equivalent" determination for EchoSolv HF. The FDA upheld that determination. In 510(k) terms, such a finding means the regulator did not accept that the product was substantially equivalent to a legally marketed device.

Options Under Consideration

The company is evaluating its options with its US regulatory and legal advisors. These include engaging with the FDA on the path forward, lodging a new 510(k) submission and pursuing further review available under FDA procedures. Echo IQ had flagged a new submission as a possible outcome in an announcement on 17 September 2026. In recent weeks it has worked with US regulatory advisors, key opinion leaders and clinical study partners to prepare for a pre-submission meeting and a potential new filing. The company says its latest correspondence with the FDA outlined a potential pathway forward, and it will seek to confirm what analysis and clinical evidence are needed to address the issues raised.

EchoSolv AS Unaffected

Echo IQ stressed that the decision does not affect EchoSolv AS, which remains FDA-cleared and commercially available in the US. The company will keep the market informed in line with its continuous disclosure obligations. It has not given a timeline for any resubmission.

Share Issue From Option Exercise

Separately, Echo IQ lodged an Appendix 2A dated 20 November 2026, applying for quotation of 1,000,000 new ordinary shares. The shares were issued on 18 November 2026 after options were exercised on 17 November 2026 under an employee incentive scheme. They were issued for cash at AU$0.25 each, or AU$250,000 in total, and none of the options were held by key management personnel. The new shares rank equally with existing shares. After quotation, the company has 741,874,779 ordinary shares on issue.

Outro

The FDA decision is a setback for one product, while the company's other cleared product remains available in the US. The timing and outcome of any new filing are still uncertain. This article is general information only and is not financial advice.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au